uniQure Announces Financial Results for Second Quarter 2015
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- S&P 500, Nasdaq advance as oil eases ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- S&P Global explores potential separation of Capital IQ business
- Equities end higher as Anthropic's IPO filing buoys AI stocks
Chardan Capital Trims PT on uniQure (QURE) to $35; Notes Uncertainty of Glybera in the U.S.
August 27, 2015 12:02 PM EDTChardan Capital trims its price target on uniQure N.V. (Nasdaq: QURE) from $40 to $35 and maintains a Buy rating following Q2 results and update issued earlier.
Analyst Gbola Amusa noted that the lowered price target stems from (1) uncertainty for Glybera... More
uniQure (QURE) Reports Q2 Loss of EUR0.51/Share
August 27, 2015 6:07 AM EDTuniQure (NASDAQ: QURE) reported Q2 EPS of (EUR0.51), versus (EUR0.87) reported last year. Revenue for the quarter came in at EUR1.04 million, versus EUR1.62 million reported last year.
Pipeline Updates
Hemophilia B: Dosing is underway in the Phase I/II study of AMT-060 in hemophilia B and the Company anticipates... More


